ATE524477T1 - Aziridinylepothilonverbindungen - Google Patents

Aziridinylepothilonverbindungen

Info

Publication number
ATE524477T1
ATE524477T1 AT07762325T AT07762325T ATE524477T1 AT E524477 T1 ATE524477 T1 AT E524477T1 AT 07762325 T AT07762325 T AT 07762325T AT 07762325 T AT07762325 T AT 07762325T AT E524477 T1 ATE524477 T1 AT E524477T1
Authority
AT
Austria
Prior art keywords
aziridinylepothilone
compounds
aziridinylepothilone compounds
Prior art date
Application number
AT07762325T
Other languages
English (en)
Inventor
Gregory D Vite
Christopher P Leamon
Iontcho R Vlahov
Kim Soong-Hoon
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE524477T1 publication Critical patent/ATE524477T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
AT07762325T 2006-05-25 2007-05-25 Aziridinylepothilonverbindungen ATE524477T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80836606P 2006-05-25 2006-05-25
PCT/US2007/069736 WO2007140297A2 (en) 2006-05-25 2007-05-25 Aziridinyl-epothilone compounds

Publications (1)

Publication Number Publication Date
ATE524477T1 true ATE524477T1 (de) 2011-09-15

Family

ID=38561739

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07762325T ATE524477T1 (de) 2006-05-25 2007-05-25 Aziridinylepothilonverbindungen

Country Status (20)

Country Link
US (2) US7872145B2 (de)
EP (1) EP2041140B1 (de)
JP (1) JP5249929B2 (de)
KR (1) KR101413955B1 (de)
CN (1) CN101495482B (de)
AR (1) AR061181A1 (de)
AT (1) ATE524477T1 (de)
AU (1) AU2007267535B2 (de)
BR (1) BRPI0712167A2 (de)
CA (1) CA2655668C (de)
EA (1) EA014872B1 (de)
ES (1) ES2371111T3 (de)
IL (1) IL195236A (de)
MX (1) MX2008014735A (de)
NO (1) NO20084742L (de)
NZ (1) NZ572763A (de)
PE (1) PE20080316A1 (de)
TW (1) TWI383985B (de)
WO (1) WO2007140297A2 (de)
ZA (1) ZA200810022B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101754969A (zh) 2007-05-25 2010-06-23 百时美施贵宝公司 制备埃坡霉素化合物和类似物的方法
CA2927832C (en) 2010-05-18 2021-03-23 Cerulean Pharma Inc. Cyclodextrin-containing polymer-therapeutic agent conjugates and their use
SG11201607818WA (en) 2014-03-20 2016-10-28 Bristol Myers Squibb Co Stabilized fibronectin based scaffold molecules
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
ES2826566T3 (es) 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
JP6622814B2 (ja) 2014-11-25 2019-12-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ イメージングのための新規ｐｄ−ｌ１結合ポリペプチド
ES2736106T3 (es) 2015-03-10 2019-12-26 Bristol Myers Squibb Co Anticuerpos que se pueden conjugar mediante la transglutaminasa y conjugados producidos a partir de ellos
AU2016271111B2 (en) 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
EP3353198B1 (de) 2015-09-23 2020-06-17 Bristol-Myers Squibb Company Glypican-3-bindende fibronektin-basierte gerüstmoleküle
US10874646B2 (en) * 2015-10-16 2020-12-29 William Marsh Rice University Epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates thereof
EP3394096A1 (de) 2015-12-21 2018-10-31 Bristol-Myers Squibb Company Variante antikörper zur stellenspezifischen konjugation
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
US20190218294A1 (en) 2016-09-09 2019-07-18 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
KR102085798B1 (ko) 2016-12-28 2020-03-06 주식회사 인투셀 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
MX2019013132A (es) 2017-05-25 2020-01-27 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
JP2022513653A (ja) 2018-11-28 2022-02-09 ブリストル－マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体
DK3886914T3 (da) 2018-11-30 2023-07-03 Bristol Myers Squibb Co Antistof omfattende en glutaminholdig letkæde-c-terminal forlængelse, konjugater deraf og fremgangsmåder samt anvendelser
WO2020123425A2 (en) 2018-12-12 2020-06-18 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
CN110563730B (zh) * 2019-07-29 2022-03-25 江苏理工学院 高纯度n10-三氟乙酰蝶酸的制备方法
US20240377413A1 (en) 2019-09-16 2024-11-14 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
CA3185968A1 (en) 2020-07-13 2022-01-20 Tony Lahoutte Antibody fragment against folr1
EP4079327A1 (de) * 2021-04-22 2022-10-26 Centaurus Polytherapeutics Nutzlasten für arzneimittelkonjugate und deren verwendung zur behandlung von krebs
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
WO2025221458A1 (en) * 2024-04-16 2025-10-23 The Texas A&M University System N-pyridinium and n-aryl aziridines as aspartate and glutamate selective covalent ligands and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6291673B1 (en) 1997-10-17 2001-09-18 Purdue Research Foundation Folic acid derivatives
US6399638B1 (en) * 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
AUPQ014799A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
US6800653B2 (en) 2001-06-01 2004-10-05 Bristol-Myers Squibb Compnay Epothilone derivatives
KR20050026033A (ko) 2002-07-31 2005-03-14 쉐링 악티엔게젤샤프트 신규 효과기 접합체, 그의 제조 방법 및 그의 약학적 용도
CA2508831C (en) 2002-12-13 2012-05-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US7601332B2 (en) * 2003-01-27 2009-10-13 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
SI1718340T1 (sl) 2004-01-30 2008-04-30 Bayer Schering Pharma Ag Novi efektorski konjugati, postopek za njihovo proizvodnjo in njihova farmacevtska uporaba
CA2583389A1 (en) 2004-10-07 2006-04-20 Emory University Multifunctional nanoparticles conjugates and their use

Also Published As

Publication number Publication date
USRE42930E1 (en) 2011-11-15
KR101413955B1 (ko) 2014-07-01
CN101495482B (zh) 2012-05-02
US7872145B2 (en) 2011-01-18
CN101495482A (zh) 2009-07-29
NO20084742L (no) 2008-12-16
EP2041140B1 (de) 2011-09-14
PE20080316A1 (es) 2008-04-10
CA2655668A1 (en) 2007-12-06
AR061181A1 (es) 2008-08-13
IL195236A0 (en) 2009-08-03
JP2009538349A (ja) 2009-11-05
ES2371111T3 (es) 2011-12-27
KR20090025266A (ko) 2009-03-10
CA2655668C (en) 2013-02-26
AU2007267535B2 (en) 2012-07-05
EP2041140A2 (de) 2009-04-01
AU2007267535A8 (en) 2011-06-09
TWI383985B (zh) 2013-02-01
ZA200810022B (en) 2011-05-25
MX2008014735A (es) 2009-02-12
AU2007267535A1 (en) 2007-12-06
WO2007140297A2 (en) 2007-12-06
IL195236A (en) 2012-12-31
JP5249929B2 (ja) 2013-07-31
US20070276018A1 (en) 2007-11-29
HK1124335A1 (en) 2009-07-10
TW200815452A (en) 2008-04-01
BRPI0712167A2 (pt) 2012-08-28
EA200802389A1 (ru) 2009-06-30
EA014872B1 (ru) 2011-02-28
WO2007140297A3 (en) 2008-01-31
NZ572763A (en) 2010-08-27

Similar Documents

Publication Publication Date Title
LTPA2020501I1 (lt) Pakeistieji enaminokarbonilo junginiai
DE602007008423D1 (de) Flüssigkeitshärtung
DE602007009267D1 (de) Reifenaufblasverfahren
DE602007001280D1 (de) Getränkeextraktor
EP2091731A4 (de) Prepreg-laminate
ATE546437T1 (de) Aminomethyl-4-imidazole
DE502007000218D1 (de) nsetzungen
DE502007002453D1 (de) Kunstoffverdichtergehäuse
DE112007003147A5 (de) Rohr-Biegevorrichtung
FI20061014A0 (fi) Diffuusiopinnoitusmenetelmä
DE602007012951D1 (de) Verbundschraubenausräumtür
DE502007005975D1 (de) Wischblatt
NO20065996L (no) SmartPacker
FI20060691A0 (fi) Laitekotelointi
ITPD20060387A1 (it) Espositore
DE112007001125A5 (de) Käfigmutter
NO20065028L (no) Limkobling
ITMI20062042A1 (it) Elettrovalvola
NO20060756L (no) Transportsystem
FR2896376B1 (fr) Desherbeuse-emietteuse
CR10205A (es) Compuestos de cinamida policiclicos
FI7103U1 (fi) Pyrstömormuska
FI7355U1 (fi) Esiintymislava
FI7437U1 (fi) Katafalkki
FI7243U1 (fi) Hiirenpyydys

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties